Antiviral agents – Page 31 – Communicable Diseases Research

Natural and Nature-Derived Products Targeting Human Coronaviruses

Review

Published on 2021-01-162022-10-30
Journal: Molecules [Category] COVID-19, MERS,

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

Article

Published on 2021-01-082022-10-28
Journal: Pharmaceuticals [Category] COVID-19,

[키워드] 2019-nCoV acute respiratory distress addition agent Antiviral agents approach beta coronavirus caused Compliance computational modeling Computational study Coronavirus-2 cysteine protease cysteine proteases Dipeptidyl peptidase 4 dipeptidyl peptidase IV inhibitors distribution DPP4 drug Drug repurposing Efficacy inhibit inhibitor inhibitors of SARS-CoV-2 investigated M pro MERS-CoV MERS-CoV CL^pro molecular docking outbreak pandemic Patient peptidase Potential profiles reduced SAR-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 M^pro dimer SARS-CoV-2 M^pro protomer serine proteases small molecule drug stability syndrome Therapies Treatment type-2 diabete type-2 diabetes Vaccine viable treatment
[DOI] 10.3390/ph14010044 PMC 바로가기 [Article Type] Article

Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Review Article

Published on 2021-01-062022-10-04
Journal: Annals of Medicine and Surgery [Category] 임상,

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

COVID-19 및 중등도 또는 중증 폐렴으로 입원한 성인에서 Tocilizumab 대 일반 치료의 효과: 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-01-012022-09-11
Journal: JAMA Internal Medicine [Category] 임상, 진단, 치료제,

[키워드] 95% CI adjusted Admission adverse event adverse events age Analysis antibiotic Anticoagulants Antiviral agents ARD assigned Bayesian C-reactive protein Care clinical clinical status clinical trial clinically conducted Consent coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 pneumonia credible interval CrI death determine did not reduce died discharge Effect Efficacy elevated Factor Fewer patients Follow-up France greater hazard ratio Health Organization hyperinflammation Identifier IMPROVE indicated intensive care intensive care unit intention-to-treat basis interleukin-6 interquartile range intravenously investigator-initiated less mechanical ventilation median moderate moderate-to-severe COVID-19 pneumonia Mortality multicenter multiplicity NIV no difference Noninvasive ventilation occurred Open-label outcome overall survival oxygen oxygen supply oxygen support Patient patients patients hospitalized patients with COVID-19 performed Pneumonia posterior probability Primary outcomes randomized clinical trial Randomly receive recruited reduced risk risk difference scale secondary Secondary outcomes Serious Adverse Events severe pneumonia survival TCZ threshold Tocilizumab treat university hospital usual care usual care alone vasopressor support Ventilation WHO-CPS women World Health Organization
[DOI] 10.1001/jamainternmed.2020.6820 PMC 바로가기 [Article Type] Randomized Controlled Trial

A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2

SARS-CoV-2의 박테리아 인공 염색체(BAC) 벡터 비감염성 복제

Article

Published on 2021-01-012022-09-11
Journal: Antiviral Research [Category] SARS, 치료제,

On-ward participation of clinical pharmacists in a Chinese intensive care unit for patients with COVID-19: A retrospective, observational study

COVID-19 환자를 위한 중국 중환자실에서 임상 약사의 지속적인 참여: 후향적 관찰 연구

Observational Study

Published on 2021-01-012022-09-11
Journal: Research in social & administrative pharmacy : RSA [Category] 신약개발, 임상, 치료제,

[키워드] accounted adverse event adverse events Antibiotics antiviral agent Antiviral agents Care China Chinese conducted Consensus coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients disease drugs dysfunction event feasible highlight hospital Infection infections intensive care intensive care unit involved Liver function medication Medication recommendation Occurrence outcomes participated Patient Pharmacists. reached recommendation recommendations reported retrospective significantly Treatment Treatment effectiveness ward were recorded with COVID-19
[DOI] 10.1016/j.sapharm.2020.06.005 PMC 바로가기 [Article Type] Observational Study

Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro

Ionophore 항생제 X-206은 시험관 내 SARS-CoV-2 감염의 강력한 억제제입니다

Article

Published on 2021-01-012022-09-11
Journal: Antiviral Research [Category] SARS, 치료제,

A Computational Approach to Explore the Interaction of Semisynthetic Nitrogenous Heterocyclic Compounds with the SARS-CoV-2 Main Protease

반합성 질소 헤테로고리 화합물과 SARS-CoV-2 주요 프로테아제의 상호 작용을 탐색하기 위한 전산 접근 방식

Article

Published on 2020-12-272022-09-10
Journal: Biomolecules [Category] Coronavirus, MERS, SARS, 치료제,

Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease

Article

Published on 2020-12-232022-10-28
Journal: Biology [Category] COVID-19,

[키워드] affecting amino acid residue Analysis analyzed antibiotic anticancer Antiviral agents approach binding free energy binding interactions carried category China computational method conformational coronavirus coronavirus disease COVID-19 database determine docked docking scores drug Drug discovery Drug repurposing DrugBank database drugs E-pharmacophore hypothesis Effectiveness evaluate exhibited experimental drug Features generate human-to-human transmission hydrophobic interaction Hypothesis identity in vitro study in vivo inhibitor Interaction M pro MERS-CoV MM/PBSA molecular docking molecular dynamics Molecular dynamics simulation novel Novel coronavirus novel coronavirus disease Potential treatment repurposing required retrieved RMSD RMSF SARS-CoV SARS-CoV-2 SARS-CoV-2 main protease screened Screening selected sequence Seven simple specific treatment Spread stability suggested targeting the disease Treatment Virtual screening were used
[DOI] 10.3390/biology10010002 PMC 바로가기 [Article Type] Article

Interpretative immune targets and contemporary position for vaccine development against SARS‐CoV‐2: A systematic review

Review

Published on 2020-12-172022-11-01
Journal: Journal of medical virology [Category] COVID-19, MERS, SARS,

[키워드] acute respiratory syndrome Antiviral agents Candidates cause clinical trials conducted coronavirus Coronaviruses COVID‐19 COVID‐19 infection criteria develop effective evaluated Evidence explained Flow Genetic genome sequence global public health immnopathology immune immune response immunodulators implementation Laboratory literature review Novel coronavirus pandemic pathogenicity promote reported required respiratory tract SARS‐CoV‐2 SARS‐CoV‐2 infection similarity Support systematic review target the vaccine Trial Vaccine vaccine candidate Vaccine development vaccine platform Vaccines virus while World Health Organization Wuhan, China
[DOI] 10.1002/jmv.26709 PMC 바로가기 [Article Type] Review